Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

By D. Dearnaley, M. Sydes, J. Graham, E. Aird, D. Bottomley, R. Cowan, R. Huddart, Chakiath C Jose, J. Matthews, J. Millar and 7 more. The Lancet Oncology, 2007

924 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/011bda6d09c72e9e01f4fd1440173ba8620eb68b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Bae
2. A. Zietman
3. J. Slater
4. J. Efstathiou
5. J. Coen
6. D. Bush
7. B. R. Jabola
8. M. Lunt

Citations in the corpus

• Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. (2017, neutral): “1-20 203 (33) 179 (30) Gleason score 3 + 3 57 (9) 56 (9) 3 + 4 382 (63) 380 (64) 4 + 3 169 (28) 162 (27) Clinical stage T1a, T1b 4 (, 1) 3 (, 1) T1c 328 (54) 308 (52) T2a 163 (27) 159 (27) T2b 73 (12) 91 (15) T2c 40 (7) 37 (6) Myocardial infarction history 57 (9) 72 (12) Treatment history* Hypertens”
• Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. (2010, background): “deprivation therapy, which confounds the interpretation of radiation efficacy, and neither reports follow-up beyond 5 years.(4,5) The only”